Core Viewpoint - Mingzhi Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, attracting attention due to its impressive financial metrics and leading position in the disposable endoscope market, while also facing challenges such as high customer concentration, declining cash flow, and increasing market competition [1][3]. Financial Performance - The company reported a gross margin of 72.62% and a net margin of 47.26% for 2024, with a significant increase in gross margin from 69.1% in 2023 to 73.7% in the first nine months of 2025, indicating strong profitability driven by vertical integration [2][4]. - Revenue for 2024 is projected at 1.41 billion RMB, a 4.4% increase from 1.35 billion RMB in 2023, while revenue growth slowed to 3.86% in the first nine months of 2025 compared to the same period in 2024 [3][4]. - Taxable profit reached 81.83 million RMB in 2024, a 28.0% increase from 63.92 million RMB in 2023, but fell by 16.2% to 58.93 million RMB in the first nine months of 2025 [4][6]. Market Position - Mingzhi Technology ranks among the top three brands in the disposable ureteroscope market in the U.S., Europe, and Japan, showcasing its international competitiveness in a highly regulated environment [3][9]. - The disposable endoscope market is expected to grow from approximately 2 billion USD in 2023 to over 6 billion USD by 2030, with a compound annual growth rate exceeding 17% [8][9]. Competitive Landscape - The market is dominated by major players such as Ambu, Boston Scientific, and Olympus, which collectively hold over 40% of the global market share, presenting significant competitive challenges for Mingzhi Technology [9][10]. - The company faces increasing pressure from local competitors in China, such as Kaili Medical, which has entered the disposable ureteroscope segment, intensifying competition [9][10]. Operational Challenges - Customer concentration remains high, with the top five customers accounting for 62.6% to 69.9% of sales from 2023 to the first nine months of 2025, indicating a dependency risk [10][11]. - The company relies heavily on distributors for revenue, with 92.8% of income coming from this channel in 2024, which may limit direct customer engagement and profit margins [10][11]. - Cash flow has deteriorated, with operating cash flow declining by 19.45% in the first nine months of 2025, attributed to increased inventory and extended accounts receivable collection periods [11][12]. Strategic Outlook - Mingzhi Technology's financial and operational indicators suggest it is at a critical juncture, needing to balance high profitability with sustainable growth strategies amid intensifying competition [7][11]. - The ability to manage operational and financial risks while leveraging technological innovation and maintaining supply chain efficiency will be crucial for the company's long-term value creation [12].

Group 1: Company Overview - Mingzhi Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with CCB International as the sole sponsor [1] - The company specializes in disposable endoscopes and has gained significant attention in the capital market due to its impressive financial metrics, including a gross margin of 72.62% and a net margin of 47.26% for 2024 [1] - Despite its high profitability, the company faces challenges such as high customer concentration, declining cash flow, and increasing market competition [1] Group 2: Business Model and Competitive Advantage - Mingzhi Technology positions itself as a "platform medical device company" with a unique vertical integration model, controlling the entire supply chain from core optical components to system assembly [2] - This vertical integration has resulted in significant cost advantages and technical control, with gross margins increasing from 69.1% in 2023 to 73.7% in the first nine months of 2025 [2][4] - The company has developed competitive products, including some of the thinnest disposable ureteroscopes and cystoscopes, which are crucial for minimally invasive surgeries [2] Group 3: Market Position and Financial Performance - By 2024, Mingzhi Technology ranks among the top three brands in the disposable ureteroscope market in the U.S., Europe, and Japan, reflecting its international competitiveness [3] - The company's revenue for 2024 is projected to be 141.05 million RMB, a 4.4% increase from 2023, but growth has shown signs of slowing down, with only a 3.86% increase in the first nine months of 2025 [3][4] - The gross profit margin has shown a consistent upward trend, but net profit has declined by 14.5% in the first nine months of 2025 compared to the same period in 2024, indicating emerging challenges in profitability [4][11] Group 4: Industry Dynamics and Challenges - The disposable endoscope market is experiencing rapid growth, with projections indicating an expansion from approximately $2 billion in 2023 to over $6 billion by 2030, reflecting a compound annual growth rate of over 17% [8][9] - However, the market is dominated by major players like Ambu, Boston Scientific, and Olympus, which collectively hold over 40% of the global market share, creating significant competitive barriers [9] - Mingzhi Technology's revenue is heavily reliant on overseas markets, exposing it to risks from geopolitical issues, currency fluctuations, and changes in international trade policies [10] Group 5: Operational Risks and Financial Health - The company has a high customer concentration, with the top five customers accounting for 62.6% to 69.9% of sales from 2023 to the first nine months of 2025, indicating a dependency risk [10] - The sales channel structure is heavily reliant on distributors, with 92.8% of revenue coming from this channel in 2024, which may limit direct customer engagement and profit margins [10] - Operational efficiency is under pressure, as evidenced by a 19.45% decline in operating cash flow in the first nine months of 2025, attributed to increased inventory and extended accounts receivable collection periods [11]

Company Overview - Mingzhi Technology Co., Ltd. is a platform-based medical device company specializing in innovative visualization and minimally invasive medical devices, particularly in the disposable urological endoscope sector [3] - The company operates in Silicon Valley and China, focusing on the research and commercialization of disposable endoscope systems [3] - Mingzhi Technology is one of the few companies globally that has successfully achieved vertical integration of the disposable endoscope supply chain, covering everything from core optoelectronic components and precision parts to complete system assembly [3] Product Portfolio - The product portfolio includes two main categories: 1. Disposable endoscopes designed for specific clinical applications such as ureteroscopes, cystoscopes, and bronchoscopes, featuring patented micro-camera modules and industry-leading micro-joint technology [4] 2. Image processors compatible with capital equipment, utilizing advanced algorithms to ensure excellent image quality and seamless user experience [4] - As of the last practicable date, the company has eight approved product categories and five in-development product categories in major global markets, including the US, EU, and China [4] Financial Performance - For the fiscal years 2023, 2024, and the nine months ending September 30, 2025, the company reported revenues of approximately RMB 135.16 million, RMB 141.05 million, and RMB 117 million, respectively [10] - The net profit for the same periods was approximately RMB 49.99 million, RMB 66.67 million, and RMB 49.92 million [10] - The gross profit margins for 2023, 2024, and the nine months ending September 30, 2025, were 69.1%, 72.6%, and 73.7%, respectively [12] Industry Overview - The global endoscope market is projected to grow from USD 16 billion in 2020 to USD 36.5 billion by 2032, with a compound annual growth rate (CAGR) of 9.5% from 2020 to 2024 and an estimated 5.9% from 2024 to 2032 [13] - The disposable endoscope market is expected to expand from USD 700 million in 2020 to USD 9 billion by 2032, with a robust CAGR of 37.8% from 2020 to 2024, slowing to 17.2% from 2024 to 2032 [16] - The fastest-growing segments within the disposable endoscope market are urology and respiratory fields, both exceeding a 34-35% CAGR in the early stages [16][17]

Company Overview - Mingzhi Technology Co., Ltd. is a platform-based medical device company specializing in innovative visualization and minimally invasive medical devices, particularly in the disposable urological endoscope sector [3][4] - The company operates in Silicon Valley and China, focusing on the research and commercialization of disposable endoscope systems [3] - Mingzhi Technology is one of the few companies globally that has successfully achieved vertical integration of the disposable endoscope supply chain, covering everything from core optoelectronic components and precision parts to complete system assembly [3] Product Portfolio - The product portfolio includes two main categories: 1. Disposable endoscopes designed for specific clinical applications such as ureteroscopes, cystoscopes, and bronchoscopes, featuring patented micro-camera modules and industry-leading micro-joints with up to 275 degrees of bidirectional deflection [3] 2. Image processors compatible with capital equipment, utilizing advanced algorithms to ensure excellent image quality and seamless user experience [3] - As of the last practicable date, the company has eight approved product categories and five in-development product categories across major global markets, including the US, EU, and China [4] Financial Performance - For the fiscal years ending September 30, 2023, 2024, and 2025, the company reported revenues of approximately RMB 135.16 million, RMB 141.05 million, and RMB 117 million, respectively [7] - The net profit for the same periods was approximately RMB 49.99 million, RMB 66.67 million, and RMB 49.92 million [7] - The gross profit margins for the fiscal years 2023, 2024, and 2025 were 69.1%, 72.6%, and 73.7%, respectively [8] Industry Overview - The global endoscope market is expected to grow from USD 16 billion in 2020 to USD 36.5 billion by 2032, with a compound annual growth rate (CAGR) of 9.5% from 2020 to 2024 and an estimated 5.9% from 2024 to 2032 [9] - The disposable endoscope market is projected to expand from USD 700 million in 2020 to USD 9 billion by 2032, with a robust CAGR of 37.8% from 2020 to 2024, slowing to 17.2% from 2024 to 2032 [12][15] - The respiratory and urological fields are the largest and fastest-growing segments, with early-stage CAGRs exceeding 34-35% [12][13]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of This Application Proof is in draft form. The information contained in it is incomplete and is subject to change whi ...

Core Viewpoint - The company reported a strong performance in H1 2025, with significant revenue growth driven by recovery in inventory levels and expansion in domestic and international markets [1][2]. Group 1: Financial Performance - In H1 2025, the company achieved revenue of 266 million yuan, a year-on-year increase of 20.50%, and a net profit attributable to shareholders of 74 million yuan, up 5.52% year-on-year [1]. - In Q2 2025, the company recorded revenue of 119 million yuan, reflecting a year-on-year growth of 15.52%, but net profit decreased by 13.55% to 28 million yuan [1]. - The gross margin improved to 65.84%, an increase of 1.75 percentage points, while the net profit margin decreased to 27.31%, down 4.35 percentage points [1]. Group 2: Operational Adjustments - The company has established production lines in Thailand for endoscopes and light source modules, significantly reducing tariff impacts on products sold to the U.S. market [2]. - A second phase of production line construction in Thailand is underway, including assembly and GMP production workshops, to support the expansion of disposable consumables and outpatient products [2]. - The company is collaborating with a major U.S. client on the next-generation endoscope system and has formed a joint venture with a German surgical instrument company to develop minimally invasive surgical instruments [2]. Group 3: Research and Development - In H1 2025, the company invested 33 million yuan in R&D, accounting for 12.5% of revenue, and expanded its product matrix with new gynecological instruments and AI-related projects to enhance endoscopic image quality [3]. - The company has submitted registration for head and neck surgical instruments and is in trial production for bladder and pediatric laparoscopes [3]. - Revenue forecasts for 2025-2027 are projected at 552 million, 676 million, and 812 million yuan, with corresponding net profits of 187 million, 234 million, and 283 million yuan, indicating strong growth potential [3].

Group 1: Haier Biomedical - The overseas revenue distribution is 40% from Europe, 30% from Africa, 20% from Asia, and 10% from the Americas, with low-temperature storage market share below 10% [1] - Smart medication and blood technology each contribute 11% to revenue, while laboratory solutions account for 17%, with the former two being more profitable [1] - The company aims for a 15%-30% revenue growth through stock incentive plans, with significant growth in domestic large projects and a nearly 200% increase in medical projects [1] Group 2: Tuojing Life - The company focuses on invasive fungal disease detection, having completed restructuring and integration to enhance product development and clinical promotion [2] - The industry is significantly impacted by centralized procurement policies, with expectations for growth in self-immune testing, HPV screening, and thrombosis detection in the future [2] - The company has made a provision for asset impairment of approximately 13.44 million yuan, mainly due to bad debt losses and inventory adjustments [2] Group 3: Haitai New Light - Most products have been transferred to Thailand for mass production, with expectations to complete all product transfer approvals by Q3 [3] - Strong demand from overseas customers is anticipated, with continued growth in overseas shipments expected in the second half of the year [3] - The company has initiated cooperation with U.S. clients for the next-generation endoscope system, expanding from general surgery to head and neck surgery and orthopedics, which is expected to drive significant business growth [3]

Core Viewpoint - The company reported a decline in revenue and net profit for 2024, but showed signs of recovery in Q4 2024 and Q1 2025, with a positive outlook for future earnings growth driven by inventory reduction among overseas clients and new product launches [1][2][4]. Financial Performance - For the full year 2024, the company achieved revenue of 443 million yuan (down 5.90%) and a net profit attributable to shareholders of 135 million yuan (down 7.11%) [1] - In Q4 2024, revenue was 124 million yuan (up 31.59%) and net profit attributable to shareholders was 38 million yuan (up 37.92%) [1] - For Q1 2025, revenue reached 147 million yuan (up 24.86%) and net profit attributable to shareholders was 47 million yuan (up 21.45%) [1] Product and Market Development - The company’s medical endoscope business generated revenue of 345 million yuan in 2024 (down 7.04%), while optical revenue was 95 million yuan (down 1.80%) [2] - International revenue for 2024 was 306 million yuan (down 6.5%), and domestic revenue was 135 million yuan (down 4.70%) [2] - The company has successfully launched a full range of laparoscopes and various endoscope products in the domestic market, and new products for the U.S. market are set to enter mass production [3] Future Outlook - The company expects net profits attributable to shareholders for 2025-2027 to be 180 million, 230 million, and 280 million yuan, representing year-on-year growth of 34.8%, 25.4%, and 23.1% respectively [4] - The estimated EPS for the same period is projected to be 1.51, 1.90, and 2.34 yuan, with corresponding PE ratios of 23, 19, and 15 times [4] - A target price of approximately 42 yuan is set for 2025, based on a valuation of 28 times [4]

Investment Rating - The report maintains a "Recommendation" rating for the company, with a target price of 42 yuan [2][9]. Core Views - The company reported a revenue of 443 million yuan for 2024, a decrease of 5.90% year-on-year, and a net profit attributable to shareholders of 135 million yuan, down 7.11% [2][4]. - In Q4 2024, the company experienced a revenue increase of 31.59% to 124 million yuan and a net profit increase of 37.92% to 38 million yuan, indicating a potential upward turning point in performance [2][4]. - The company plans to distribute a cash dividend of 0.6 yuan per share (before tax) to all shareholders [2]. Financial Summary - Total revenue is projected to grow from 443 million yuan in 2024 to 828 million yuan by 2027, with a compound annual growth rate (CAGR) of 21.3% [4]. - Net profit is expected to increase from 136 million yuan in 2024 to 281 million yuan in 2027, reflecting a CAGR of 23.1% [4]. - Earnings per share (EPS) are forecasted to rise from 1.12 yuan in 2024 to 2.34 yuan in 2027, with corresponding price-to-earnings (P/E) ratios decreasing from 31 to 15 [4][9]. Business Performance Insights - The company's medical endoscope business generated 345 million yuan in revenue for 2024, down 7.04%, while optical revenue was 95 million yuan, down 1.80% [9]. - International revenue for 2024 was 306 million yuan, a decrease of 6.5%, while domestic revenue was 135 million yuan, down 4.70% [9]. - The company has a backlog of 360 million yuan in orders from major clients as of the end of 2024, indicating strong future demand [9]. Product Development and Market Expansion - The company has successfully completed certifications for its overseas subsidiaries, reducing trade friction risks and enabling smoother order fulfillment in the U.S. market [9]. - New product registrations for various endoscope products targeting domestic markets have been completed, and new models for the U.S. market are set to enter mass production [9].